anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: veterinary science. SUBSTANCE: preparation has 16.7-83.3 wt.-% of rifampicin and 16.7-83.3 wt.-% of doxycyclin as active components. By the second variant the antibacterial preparation has the above indicated active components and pharmacologically acceptable solvent and/or diluting agent at the following ratio of components, wt.-%: rifampicin 0.3-3.0; doxycyclin 0.3-3.0 and solvent and/or diluting agent - the rest. Methods of treatment of animals with mastitis and endometritis are based on the use of the new antibacterial preparation taken at the definite therapeutic doses and sequence. The preparation is stable at storage for 3 years and shows the enhanced therapeutic activity. EFFECT: broadened spectrum of an antibacterial effect, decreased treatment period and possibility of relapses. 5 cl, 1 tbl, 20 ex
Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. VOTRIENT is not indicated for use in combination with other agents. Six of the 7 TMA cases occurred within 90 days of the initiation of VOTRIENT. Improvement of TMA was observed after treatment was discontinued.

Monitor for signs and symptoms of TMA. Permanently discontinue VOTRIENT in patients developing TMA. Manage as clinically indicated.
The present invention relates to the preparation of amino acid containing compounds which also have multiple carboxylic acid functional groups. Paramagnetic metal (II) or (III) ion chelate complexes are formed using these compounds for use as intravenous contrast agents to produce enhanced contrast magnetic resonance images of the heart, liver, biliary tree or upper small intestine. The mono and di-amino acids (and their carboxylic esters carboxylic amides, and catechols) of EDTA, DTPA, and the like are prepared.  The paramagnetic metal (II) or (III) ion complexes are formed and produce T1-related contrast effects in MR images. The compounds and complexes also appear to have low toxicities and to be relatively rapidly and completely cleared from the tissue of a living mammal, e.g. a human being.
This is a two-arm, 14 month pragmatic cluster randomized trial to evaluate the added benefit of EE-CTH relative to CTH for patients with T2DM in primary care.

Primary care practices (not patients) will be randomly assigned to receive and deliver CTH or EE-CTH in an innovative effectiveness-implementation hybrid design. Using the RE-AIM framework, the investigators will evaluate program effectiveness in a real world setting, while at the same time gathering information on program reach, adoption, implementation and maintenance. CTH and EE-CTH practice trainings and delivery will each follow separate and standardized protocols, with support provided to practices through staff training, ongoing supervision and case presentations, and a practice improvement team assisted by a practice facilitator to address issues of staffing and patient flow. Practice training and facilitation notes, in conjunction with feedback from patient advisory councils, will be captured and integrated to identify barriers and facilitators to the implementation process and inform dissemination efforts. Beyond the requirements of the study, practices will be permitted to use EE-CTH or CTH with other patients as wished, which will enable the investigators to document the program's reach within the practice. Patients in both study arms will receive the intervention at a minimum of two primary care appointments (baseline and follow-up between 6 and 12 months).
Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
PROBLEM TO BE SOLVED: To obtain an emulsifier capable of preparing an emulsified compsn. and emulsified cosmetics each having satisfactory stability of the emulsified state, satisfactory safety and appliability. SOLUTION: This emulsifier is made of a water-soluble amphiphilic polyelectrolyte contg. (meth)acrylamidoalkylsulfonic acid units by >=60wt.% of the total amt. and obtd. by copolymerizing (meth)acrylamidoalkylsulfonic acid and/or its salt with a (meth)acrylate or further neutralizing the resultant copolymer with an alkali agent.
Swiss ball exercises will be administered. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
This group follows a treatment prescribed by a therapist using Muvity, a telerehabilitation system using a depth camera. The treatment consists of some exercises guided by a virtual avatar, and some exergames to play. The computer application monitors the ranges of motion of joint angles as well as time played and deviations from theoretical trajectories. These sessions are programmed to be done in three 30-min-sessions per week, during 12 weeks (same amount as the Control group).
Process for producing microparticles is characterised in that 'it arises by a controlled demulsification process in a step for forming a drug-loaded polymer matrix, which is surrounded by a shell of a second polymer'. Also claimed are microparticles produced by the above process, where: (1) the particles have an ave. dia. below 50 microns and contain water-soluble drugs; (2) the particles permit oral admin. of bad-tasting water-soluble drugs in a neutral-tasting form; or (3) the particles are capable of releasing the drug in a pH-dependent manner, the pH range for release being controllable by the choice of synthetic polymers. Also claimed are pharmaceutical compsns. comprising microparticles produced by the above process and any additives, which can be suspended in a liq. before oral ingestion. The particles are formed by solidification of several polymers dissolved in the internal phase of an emulsion, both by solvent evapn. and by addn. of a non-solvent.
Participants in the experimental group (EG) undergo the exercise program designed for the purpose of the study. The outdoor sessions will be carried out in groups (2 sessions per week, lasting 1 hour each one) and administered by trainers with a master's degree in Science and Technique of Preventive and Adapted Physical Activity (kinesiologists).
PROBLEM TO BE SOLVED: To obtain composite skin beautifying effects by using only natural materials and mixing a plurality of the simple materials effective for health or the skin. SOLUTION: This liquid 7 for the cosmetic is used directly by dipping a plurality of natural ores 9, etc., in water of a container body 8 or stirring the mixture. The natural ores 9 are composed of nearly equal amounts of quartz, alkali feldspar and plagioclase and is a leucocratic medium granular or coarse granular granite containing a small amount of biotite. The mineral is quartz, cristobalite, plagioclase kaolin, montmorillonite or a mixed layer clay mineral. The natural ores 9 are capable of producing a large amount of negative ions and radiating far infrared rays. A larger amount of negative ions of the natural ores 9 is produced by mutually receiving shock by the ores 9. Thereby, a plurality, at least >=2 natural ores 9, etc., are dipped in the container body 8.
Method for assistance in the selection of the medical specialty and communication with the specialist doctor through a mobile device. Method for the help of clinical decision making through a mobile device. A user introduces symptoms of a disease to be diagnosed in a user mobile device terminal, and sends them through the internet (10) to a remote server (21), endowed with a database of symptoms, specialties and diseases (22). ) and a program to manage symptoms, specialties and diseases. The mobile user device is communicated with a computer device (25) of a medical specialist available, also connected through the wan (10), with which the mobile user device performs a chat after which the medical specialist diagnoses the illness. The program can select at least one medical specialty from the symptoms introduced and display the selected medical specialties on the user's mobile device display, so that the user can choose a medical specialty. (Machine-translation by Google Translate, not legally binding)
The present invention relates to medical device applications technical fields, and its purpose is to provide a kind of Medical Devices access times control system and its working methods.The invention discloses a kind of Medical Devices access times control systems, including the first power module, switch module and Medical Devices ontology being sequentially connected electrically；It further include operating terminal and server.The invention also discloses a kind of working methods of Medical Devices access times control system, comprising the following steps: S1. operating terminal receives checking request and sends it to server；S2. server receives checking request；S3. server judges whether the number of operations of the operating terminal is less than the predetermined access times that the operating terminal corresponds to Medical Devices, if being then proved to be successful, subsequently into step S4；S4. server is sent using enabling signal to operating terminal, and operating terminal, which receives, uses enabling signal, then sends closure signal to switch module；S5. switch module is closed.The present invention can limit the access times of Medical Devices.
This qualitative study aimed to explore the experiences of 11 adults with chronic kidney disease (CKD) undergoing evaluation for kidney transplant (KT) and examine the role played by the nurse in the process. Employing a descriptive phenomenology approach, semi-structured interviews were conducted between October 2022 and July 2023. Thematic analysis, facilitated by Atlas. ti software, revealed a systemic management diagram with "The candidate for kidney transplant and their reality" at the center, followed by "The process of chronic kidney disease and kidney transplantation," and concluding with the most distal category centered on "The kidney transplant access nurse." This organizational framework provided insights into the layers of relationships between emerging themes. The findings underscored the complexity and multidimensionality of the CKD and KT process, emphasizing the nurse's pivotal role as a guide and protector throughout the evaluation process for accessing kidney transplantation. The convergence of results with existing literature highlighted the need to address challenges such as lack of time, resources, and emotional support to enhance the quality of care. Recognizing the nurse's crucial importance in this process, the study emphasizes the significance of addressing these challenges to improve patient care and calls for attention to the nurse's role in guiding individuals through the intricate journey of CKD and kidney transplantation.
FIELD: medicine, neurosurgery. SUBSTANCE: the suggested method deals with treating patients with developed secondary cerebral vasospasm after subarachnoidal hemorrhage as a result of arterial aneurism rupture of cerebral vessels. One should carry out clipping of arterial aneurism simultaneously with applying extraintracranial microvascular anastomosis (EICMA) between the branch of ipsilateral surface temporal artery and cortical branch of middle cerebral artery. Therapy course should be conducted including maintenance of systolic arterial pressure being 25-30% higher against "working" one and normovolemic variant of hemodilution. Moreover, minimum volume of infusion should be performed in nocturnal hours, and ratio of enterally injected liquid and intravenous infusion should be maintained to be 1: 6 during the 1st d, and then - 1:2. EFFECT: higher efficiency of therapy. 1 cl, 1 ex
The outbreak of COVID-19 and its global pandemic have posed a threat to public health. The deadly virus, SARS-CoV-2, has been evolving to new, more infectious variant and other lineages with additional immune escape mutations. The highly transmissible Omicron variant has been present for around one year and has supplanted Delta as the leading strain in the global pandemic. Despite the fact that 656 million people have been infected with SARS-CoV-2 worldwide as of January 1, 2023, asymptomatic infections and mild cases account for more than 90% because of its notably declined pathogenicity.As of December 20, 2022, more than 130 sub-branches of Omicron have been imported into China, with BA.5.2 and BF.7 being the most prevalent strains.

On December 7, 2022, the State Council of China issued an announcement on further optimization of measures for preventing and controlling the COVID-19 epidemic ( easing of rigorous "zero COVID" policies). Since then, the rapid spread of COVID-19 has caused a surge of COVID-19 infections in the majority of China. As of January 6, a total of 503302 individuals have been infected. Consequently, the proportion of surgical patients with current or previous SARS-CoV-2 infections will inevitably increase within a short period of time. It has been reported that recovery from SARS-CoV-2 infection is associated with a transiently elevated risk of postoperative complications. The longer the time interval between SARS-CoV-2 infection and surgery, the lower the risk of postoperative complications. An updated recommendation suggested postponing surgery for at least seven weeks following SARS-CoV-2 infection, thereby reducing the risk of postoperative complications and 30-day mortality to baseline levels (similar risk with patients without a history of SARS-CoV-2 infection). However, these recommendations were based on limited data from the earlier Covid-19 pandemic (mostly caused by the Delta strain) in Europe and the United States It may not be feasible to generalize and apply this experience and consensus to the Chinese population and use it to guide current practice.

In this prospective cohort study, the postoperative complications will be described and compared in patients with or without Covid-19 infection. In addition, risk factors in the patients and surgical levels that are associated with an increase in postoperative morbidities and mortalities will be assessed.
SIMBRINZA contains brinzolamide, a sulfonamide, and although administered topically is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of SIMBRINZA. Fatalities have occurred due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is re-administered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation immediately. [see Adverse Reactions (6.2) and Patient Counseling Information (17)].
The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
Infection is more common in patients who received a high number of blood transfusions before 1990. The prevalence of HCV infection is higher in Italy, where more than 70% of thalassemia major patients are HCV-RNA positive. In Italy and worldwide, genotype 1 is the most frequent. Regarding the prevalence of cirrhosis, the clinical data of different cohorts of thalassemia patients showed a rate of cirrhosis ranging from 10% to 20%. Male sex, high serum ALT values, and a positive serum test for qualitative HCV-RNA are significantly associated with severe fibrosis or cirrhosis. Cirrhosis related to hepatitis C virus infection is the major risk factor for development of hepatocellular carcinoma and is a major cause of liver failure. An Italian study that reported clinical data of 22 thalassemia patients with hepatocellular carcinoma concluded that the development of hepatocellular carcinoma is associated with the presence of cirrhosis, male gender, age over 35 years, and active HCV infection. Another prospective study reported a 2% incidence of new HCC during the follow-up of 105 adult thalassemia patients cohort. Yet before 2000, several controlled trials reported that combination therapy with alpha-interferon, given three times a week, and ribavirin, given every day, was more effective than interferon alone.Recently, three different studies reported the efficacy and the safety of combination therapy with pegylated interferon and ribavirin in thalassemic patients. Less extensive data are present actually in literature about efficacy of combination therapy with pegylated interferon and ribavirin in HCV infected patients with sickle cell disease or sickle/beta-thalassemia.
Background: Lymphedema is a common complication after mastectomy in women with breast cancer. Several methods have been described to assess and diagnose lymphedema, one of the most studied being the perimeter and ultrasonography. However, the reliability of these methods and the correlation between them are still controversial. The aim of this study was to analyze the reliability of cytometry and ultrasound imaging in the assessment of lymphedema after mastectomy in women with breast cancer and to study the correlation between them. Methods and Results: A cross-sectional study was conducted in 29 women with mastectomy after breast cancer. Lymphedema in the arm was measured both with cytometry and ultrasonography. Reliability was calculated with intraclass correlation coefficient. The correlation between the two methods was carried out with the Pearson correlation coefficient. Both cytometry (M1: α = 0.999, ICC = 0.996; M2: = α = 0.998, ICC = 0.994) and ultrasonography (M1: α = 0.992, ICC = 0.976; M2: = α = 0.991, ICC = 0.973) are reliable methods to assess lymphedema in the arm. No significant correlation was found between them (p > 0.05). Conclusions: Cytometry and ultrasonography appear to be adequate for the measurement of edema in women with breast cancer after mastectomy. However, for an accurate measurement of lymphedema, these measurements should not be used interchangeably.
BACKGROUND: Gene variants are responsible for more than half of hearing loss, particularly in nonsyndromic hearing loss (NSHL). The most common pathogenic variant in SLC26A4 gene found in East Asian populations is c.919-2A > G followed by c.2168A > G (p.H723R). This study was to evaluate their variant frequencies in patients with NSHL from special education schools in nine different areas of Southwest China's Yunnan.
METHODS: We performed molecular characterization by PCR-products directly Sanger sequencing of the SLC26A4 c.919-2AG and c.2168 A > G variants in 1167 patients with NSHL including 533 Han Chinese and 634 ethnic minorities.
RESULTS: The SLC26A4 c.919-2A > G variant was discovered in 8 patients with a homozygous state (0.69%) and twenty-five heterozygous (2.14%) in 1167 patients with NSHL. The total carrier rate of the c.919-2A > G variant was found in Han Chinese patients with 4.50% and ethnic minority patients with 1.42%. A significant difference existed between the two groups (P < 0.05). The c.919-2A > G allele variant frequency was ranged from 3.93% in Kunming to zero in Lincang and Nvjiang areas of Yunnan. We further detected the SLC26A4 c.2168 A > G variant in this cohort with one homozygotes (0.09%) and seven heterozygotes (0.60%), which was detected in Baoshan, Honghe, Licang and Pu`er areas. Between Han Chinese group (0.94%) and ethnic minority group (0.47%), there was no statistical significance (P > 0.05). Three Han Chinese patients (0.26%) carried compound heterozygosity for c.919-2A > G and c.2168 A > G.
CONCLUSION: These data suggest that the variants in both SLC26A4 c.919-2A > G and c.2168 A > G were relatively less frequencies in this cohort compared to the average levels in most regions of China, as well as significantly lower than that in Han-Chinese patients. These results broadened Chinese population genetic information resources and provided more detailed information for regional genetic counselling for Yunnan.
Lamivudine is a synthetic nucleoside analogue with activity against HIV-1 and HBV. The drug substance used in lamivudine tablets, USP 150 mg and 300 mg is lamivudine in the form of lamivudine methanol solvate. The chemical name of lamivudine methanol solvate is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone methanol solvate. It has a molecular formula of C8H11N3O3S·0.2CH4O and a molecular weight of 235.66 g/mol. It has the following structural formula: 

Lamivudine methanol solvate is a white to off-white powder. It is highly soluble in water. 

Lamivudine tablets, USP are for oral administration. Each scored 150-mg film-coated tablet contains lamivudine methanol solvate equivalent to 150 mg of lamivudine and the inactive ingredients colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol and titanium dioxide. 

Each 300-mg film-coated tablet contains lamivudine methanol solvate equivalent to 300 mg of lamivudine, and the inactive ingredients colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, iron oxide black, lactose anhydrous, magnesium stearate, polyethylene glycol and titanium dioxide.

Meets USP Dissolution Test 2.
Patients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.
On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.